- Stocks
- Pharma & Healthcare
- Vivimed Labs
Vivimed Labs share price
NSE: VIVIMEDLABPharma & HealthcareDrug Manufacturers - Specialty & Generic
Vivimed Labs at a glance
Vivimed Labs (NSE: VIVIMEDLAB) closed at ₹6.21 on 22 Oct 2026, down 1.90% on the day. With a market capitalisation of ₹51 Cr, it ranks 3055th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
Its return on equity was 0.0% in FY25. Over the past year the share price has fallen 45.8%. Its 52-week range is ₹4.75 (11 Aug 2026) to ₹29.40 (18 Dec 2025); the last close is 78.9% below the high. In Q4 FY26, the quarter ended 31 Mar 2026, revenue was ₹12 Cr (−53.1% year on year) and net profit −₹147 Cr, on a consolidated basis. Promoters held 7.57% of the company as of 31 Mar 2026; 15.18% of promoter shares were pledged.
Key numbers
- Market cap
- ₹51 CrRank 3055 on NSE
- Price to book
- 0×FY25
- EPS (TTM)
- −₹21.28to Q4 FY26
- ROE
- 0.0%FY25
- ROCE
- −5.6%FY25
- Debt to equity
- -5.14FY25
- Net profit margin
- −27.5%FY25
- Book value / share
- −₹8.82FY25
- 52-week high
- ₹29.4018 Dec 2025
- 52-week low
- ₹4.7511 Aug 2026
- 1-year return
- −45.8%
- RSI (14-day)
- 47.7
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −1.90% | −9.2% | +13.5% | +19.7% | −45.8% |
Vivimed Labs quarterly results
| Quarter | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹29 Cr | ₹25 Cr | ₹37 Cr | ₹26 Cr | ₹21 Cr | ₹21 Cr | ₹16 Cr | ₹12 Cr |
| Revenue YoY | −16.9% | −26.4% | −11.9% | −33.7% | −27.2% | −16.8% | −56.2% | −53.1% |
| Net profit | −₹15 Cr | −₹5 Cr | −₹6 Cr | −₹6 Cr | −₹5 Cr | −₹7 Cr | −₹17 Cr | −₹147 Cr |
| Net profit YoY | — | — | — | −206.5% | — | — | — | — |
| Net margin | −51.9% | −20.8% | −16.4% | −21.9% | −25.7% | −35.4% | −103.5% | −1,226.0% |
| EPS | −₹1.84 | −₹0.63 | −₹0.72 | −₹0.68 | −₹0.66 | −₹0.88 | −₹2.00 | −₹17.74 |
Vivimed Labs financials
| Item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|
| Revenue | ₹1,059 Cr | ₹861 Cr | ₹237 Cr | ₹187 Cr | ₹149 Cr | ₹116 Cr |
| Operating profit | −₹109 Cr | −₹70 Cr | −₹65 Cr | −₹331 Cr | −₹40 Cr | −₹32 Cr |
| Net profit | −₹109 Cr | −₹72 Cr | −₹68 Cr | −₹329 Cr | −₹45 Cr | −₹32 Cr |
| EPS (₹) | −₹13.00 | −₹9.00 | −₹8.00 | −₹40.00 | −₹5.00 | −₹4.00 |
| Cash from operations | ₹80 Cr | ₹567 Cr | ₹28 Cr | ₹35 Cr | −₹24 Cr | −₹2 Cr |
| Total debt | ₹470 Cr | ₹58 Cr | ₹61 Cr | ₹62 Cr | ₹64 Cr | ₹64 Cr |
| Shareholders' equity | ₹509 Cr | ₹432 Cr | ₹364 Cr | ₹39 Cr | −₹5 Cr | −₹35 Cr |
Vivimed Labs shareholding pattern
| Holder | 31 Dec 2024 | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 20.94% | 20.94% | 7.77% | 7.77% | 7.77% | 7.57% |
| Foreign institutions | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% | 1.64% |
| Domestic institutions | — | — | — | — | 0.00% | 0.00% |
| Non-institutions | 77.30% | 77.30% | 90.48% | 90.48% | 90.48% | 90.67% |
| Promoter shares pledged | 37.06% | 37.06% | 14.80% | 14.80% | 14.80% | 15.18% |
Vivimed Labs vs peers
The listed Pharma & Healthcare companies nearest to Vivimed Labs by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| KABRADGKabra Drugs | — | — | — | ₹56 Cr | — | — |
| BANDARAMBandaram Pharma | — | — | — | ₹53 Cr | — | — |
| VRLVasundhara Ras | — | — | — | ₹53 Cr | — | — |
| VIVIMEDLABVivimed Labs | ₹6.21 | −1.90% | −45.8% | ₹51 Cr | — | — |
| SHREEPACShree Pacetroni | — | — | — | ₹50 Cr | — | — |
| BIOFILCHEMBiofil Chemicals & Pharmaceuticals | ₹30.00 | +2.15% | −27.3% | ₹49 Cr | 17.5 | — |
| SHANMUGAShanmuga Hospit | — | — | — | ₹48 Cr | — | — |
Ask anything about Vivimed Labs
Pivot answers on the live chart with evidence you can check, and tests strategies against VIVIMEDLAB's own history. Try: “Why has VIVIMEDLAB moved over the last three months?” · “Backtest a 50-day moving-average crossover on VIVIMEDLAB over five years” · “Compare VIVIMEDLAB with KABRADG on margins and valuation”
Frequently asked questions about Vivimed Labs
What is the share price of Vivimed Labs today?
Vivimed Labs (NSE: VIVIMEDLAB) last closed at ₹6.21 on 22 Oct 2026. Its 52-week high is ₹29.40 and its 52-week low is ₹4.75.
What is the market cap of Vivimed Labs?
Vivimed Labs' market capitalisation is ₹51 Cr (₹51 Cr) at the 22 Oct 2026 close, ranking 3055th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Vivimed Labs?
Return on equity was 0.0% in FY25 and return on capital employed was −5.6% in FY25 (consolidated figures).
Is Vivimed Labs a debt-free company?
Vivimed Labs is close to debt-free: its debt-to-equity ratio was -5.14 in FY25.
What were Vivimed Labs' latest quarterly results?
For Q4 FY26 (quarter ended 31 Mar 2026), Vivimed Labs reported revenue of ₹12 Cr, −53.1% year on year, and net profit of −₹147 Cr.
How has Vivimed Labs stock performed over the last year?
Vivimed Labs' share price has fallen 45.8% over the past year, +19.7% over three months and +13.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Vivimed Labs?
As of 31 Mar 2026: promoters 7.57%, foreign institutions 1.64%, domestic institutions 0.00%, non-institutions 90.67%. 15.18% of promoter shares were pledged.
Who are Vivimed Labs' competitors?
The listed Pharma & Healthcare companies closest to Vivimed Labs by market cap are Kabra Drugs, Bandaram Pharma, Vasundhara Ras, Shree Pacetroni, Biofil Chemicals & Pharmaceuticals and Shanmuga Hospit.
Is Vivimed Labs a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Vivimed Labs' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on VIVIMEDLAB against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with V · all NSE stocks · this page as text